Another Forward Step of Laboratory Standardization in Diagnostic Procedure
In medical transplant cases, finding allogeneic stem cells are one challenge, according to the statistics, there are about 50,000 people a year urgently require a stem cell transplant; while another challenge is the precision and speed of detecting the difference between donors and recipient which determines the following measures.
Among these detections, human leukocyte antigen (HLAs) is used to determine compatibility between the tissues of different individuals (histocompatibility). Detection of the smallest individual differences in HLA sequences makes it possible to match donors and recipients at an early stage so as to adapt preventive and therapeutic measures, thus markedly reducing the rate of rejection reactions.
Congratulations, lately a laboratory in Europe, the Red Cross Blood Transfusion Service of Upper Austria, became the first one that got the accreditation of European Federation for Immunogenetics (EFI) for the use of HLA tests based on next-generation sequencing with Roche’s GS Junior System.
This new technology will allow more precise and much more rapid tissue-typing and donor selection for stem cell transplants than has been possible to date. In addition, the HLA testing method previously only used for research will now also be available as a standard routine diagnostic procedure.